195 related articles for article (PubMed ID: 20878131)
1. Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines.
Schiapparelli P; Enguita-Germán M; Balbuena J; Rey JA; Lázcoz P; Castresana JS
Oncol Rep; 2010 Nov; 24(5):1355-62. PubMed ID: 20878131
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
4. Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells.
Xue ZX; Zheng JH; Zheng ZQ; Cai JL; Ye XH; Wang C; Sun WJ; Zhou X; Lu MD; Li PH; Cai ZZ
World J Surg Oncol; 2014 Dec; 12():404. PubMed ID: 25551472
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.
Friel AM; Zhang L; Curley MD; Therrien VA; Sergent PA; Belden SE; Borger DR; Mohapatra G; Zukerberg LR; Foster R; Rueda BR
Reprod Biol Endocrinol; 2010 Dec; 8():147. PubMed ID: 21122138
[TBL] [Abstract][Full Text] [Related]
6. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
7. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
9. A distinct gene expression signature characterizes human neuroblastoma cancer stem cells.
Ross RA; Walton JD; Han D; Guo HF; Cheung NK
Stem Cell Res; 2015 Sep; 15(2):419-26. PubMed ID: 26342562
[TBL] [Abstract][Full Text] [Related]
10. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks.
Tabu K; Kimura T; Sasai K; Wang L; Bizen N; Nishihara H; Taga T; Tanaka S
Mol Cancer; 2010 Feb; 9():39. PubMed ID: 20167130
[TBL] [Abstract][Full Text] [Related]
11. Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines.
Veselska R; Hermanova M; Loja T; Chlapek P; Zambo I; Vesely K; Zitterbart K; Sterba J
BMC Cancer; 2008 Oct; 8():300. PubMed ID: 18925963
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers.
Jeon YK; Kim SH; Choi SH; Kim KH; Yoo BC; Ku JL; Park JG
World J Gastroenterol; 2010 Jul; 16(25):3153-60. PubMed ID: 20593500
[TBL] [Abstract][Full Text] [Related]
13. Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents.
Vangipuram SD; Wang ZJ; Lyman WD
Pediatr Blood Cancer; 2010 Mar; 54(3):361-8. PubMed ID: 19927294
[TBL] [Abstract][Full Text] [Related]
14. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
[TBL] [Abstract][Full Text] [Related]
15. Biological and genetic characteristics of tumor-initiating cells in colon cancer.
Ieta K; Tanaka F; Haraguchi N; Kita Y; Sakashita H; Mimori K; Matsumoto T; Inoue H; Kuwano H; Mori M
Ann Surg Oncol; 2008 Feb; 15(2):638-48. PubMed ID: 17932721
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.
Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW
Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer.
Pellacani D; Packer RJ; Frame FM; Oldridge EE; Berry PA; Labarthe MC; Stower MJ; Simms MS; Collins AT; Maitland NJ
Mol Cancer; 2011 Jul; 10():94. PubMed ID: 21801380
[TBL] [Abstract][Full Text] [Related]
19. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
20. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component.
Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J
Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
